SCHEMBL687980

SCHEMBL687980

CCOc1cc([C@H](CC(=O)O)NC(=O)Nc2c(O)c(C)cn(Cc3ccccc3Cl)c2=O)ccc1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 7/20 0.41
ITGA4 P13612 7/20 0.41
SMN1; SMN2 Q16637 1/20 0.38
PTGER3 P43115 4/20 0.37
CNR2 P34972 1/20 0.36
KMT2A Q03164 1/20 0.35
LMNA P02545 1/20 0.35
CYP26A1 O43174 1/20 0.35
SLC22A12 Q96S37 1/20 0.34
CTSA P10619 2/20 0.34
ROCK2 O75116 1/20 0.34
ROCK1 Q13464 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL687242 0.93 SMN1; SMN2 (0.44) ITGB1ITGA4SMN1; SMN2PTGER3CNR2
SCHEMBL687744 0.88 PTGER3 (0.43) PTGER3CNR2LMNASLC22A12CTSA
SCHEMBL688233 0.87 PTGER3 (0.43) SMN1; SMN2PTGER3CNR2CYP26A1SLC22A12
SCHEMBL687640 0.87 PTGER3 (0.40) ITGB1ITGA4PTGER3CNR2LMNA
SCHEMBL687923 0.86 PTGER3 (0.41) ITGB1ITGA4PTGER3CNR2SLC22A12
SCHEMBL688669 0.86 PTGER3 (0.42) ITGB1ITGA4PTGER3CNR2CTSA
SCHEMBL688215 0.86 PTGER3 (0.43) ITGB1ITGA4PTGER3CTSA
SCHEMBL688170 0.86 PTGER3 (0.41) ITGB1ITGA4SMN1; SMN2PTGER3CNR2
SCHEMBL687765 0.86 KMT2A (0.37) ITGB1ITGA4SMN1; SMN2PTGER3KMT2A
SCHEMBL688343 0.85 PTGER3 (0.43) SMN1; SMN2PTGER3CNR2SLC22A12CTSA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1203766-B1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC (US) 2012-02-29 EP disclosed
EP-1203766-A2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors TEXAS BIOTECHNOLOGY CORPORATION (US) 2002-05-08 EP disclosed